Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.

Article  CAS  PubMed  Google Scholar 

Meisel JL, Venur VA, Gnant M, Carey L. Evolution of targeted therapy in breast cancer: where precision medicine began. Am Soc Clin Oncol Educ Book. 2018;38:78–86.https://doi.org/10.1200/EDBK_201037

Arora S, Narayan P, Osgood CL, Wedam S, Prowell TM, Gao JJ, et al. U.S. FDA drug approvals for breast cancer: a decade in review. Clin Cancer Res. 2022;28:1072–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. JCO. 2022;40:3246–56.

Article  CAS  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, De Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.

Article  CAS  PubMed  Google Scholar 

Oliveira M, Pominchuck D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al. Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 2023;83:GS3-02-GS3-02.

Article  Google Scholar 

Jhaveri KL, Jeselsohn R, Lim E, Hamilton EP, Yonemori K, Beck JT, et al. A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER. JCO. 2022;40:1021–1021.

Article  Google Scholar 

Cortés J, Hurvitz SA, O’Shaughnessy J, Delaloge S, Iwata H, Rugo HS, et al. Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: primary results from AMEERA-5. JCO. 2024;2680–2690. https://doi.org/10.1200/JCO.23.02036

Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. JCO. 2024;42:2149–60.

Article  Google Scholar 

Hurvitz SA, Schott A, Ma CX, Nanda R, Zahrah G, Hunter N, et al. 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 2023;8:101394.

Article  Google Scholar 

Campone M, Ma CX, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, et al. VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. JCO. 2023;41:TPS1122–TPS1122.

Article  Google Scholar 

Wander S, Hamilton E, Campone M, Danso M, Hurvitz S, Iwata H, et al. Abstract PO2–20–03: VERITAC-3: A randomized phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Cancer Res. 2024;84:PO2-20-03-PO2-20-03.

Article  Google Scholar 

Patel MR, Layman RM, Danso MA, Cosgrove D, Zettler ME, Pehlivan KC, et al. Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. JCO. 2024;42:3074–3074.

Article  Google Scholar 

The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

Article  PubMed Central  Google Scholar 

Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol. 2022;19:471–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25:e139–51.

Article  CAS  PubMed  Google Scholar 

Castel P, Toska E, Engelman JA, Scaltriti M. The present and future of PI3K inhibitors for cancer therapy. Nat Cancer. 2021;2:587–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:87–100.

Article  PubMed  Google Scholar 

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dent S, Cortés J, Im Y-H, Diéras V, Harbeck N, Krop IE, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32:197–207.

Article  CAS  PubMed  Google Scholar 

Jhaveri KL, Seock-Ah I, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Lei G, Stout T, Hutchinson KE, Schutzman J, Song C, Turner NC. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS03-13.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA -mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929–40.

Article  PubMed  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

Article  CAS  PubMed  Google Scholar 

Burnett GL, Yang YC, Aggen JB, Pitzen J, Gliedt MK, Semko CM, et al. Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors. J Med Chem. 2023;66:149–69.

Article  CAS  PubMed  Google Scholar 

MacDougall JR, Bradley J, Mak R, Dhawan N, Chen W. Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models. Can Res. 2023;83:4946–4946.

Article  Google Scholar 

Puca L, Dowless MS, Perez-Ferreiro CM, Ortiz-Ruiz MJ, Donoho GP, Capen A, et al. Abstract P4–08–02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models. Cancer Res. 2023;83:P4-08-02-P4-08-02.

Article  Google Scholar 

Buckbinder L, St. Jean DJ, Tieu T, Ladd B, Hilbert B, Wang W, et al. STX-478, a mutant-selective, allosteric PI3Kα inhibitor spares metabolic dysfunction and improves therapeutic response in PI3Kα-mutant xenografts. Cancer Discov. 2023;13:2432–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discov. 2024;14:240–57.

Article  CAS  PubMed  Google Scholar 

METABRIC Group, Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.

Article